News
A Surbiton couple is backing a UK-wide campaign to raise awareness of a rare form of epilepsy that affects their daughter. Jennifer and Tom Allen's nine-year-old daughter, Beth, has Dravet Syndrome.
The company has already secured approval for Fintepla in treating Dravet syndrome and Lennox-Gastaut syndrome.
A little baby suffering a seizure is an incredibly distressing event for a family. Epilepsy is the most common neurological disorder in children and it takes the form of recurring seizures. But ...
The increasing incidence of genetic and rare diseases is a major factor driving revenue growth in the Antisense ...
Alternative therapies, like medical cannabis, may help people manage their seizures better. They can be included alongside your normal treatment plan.
14d
LondonWorld on MSNSurbiton family back UK wide campaign for greater awareness of rare condition which affects their daughterA Surbiton couple, whose 9 year-old daughter has Dravet Syndrome, a rare, life-limiting, form of epilepsy, are backing a ...
Dravet Syndrome occurs in around one in every 15,000 live births and is among the most treatment-resistant genetic epilepsies.
UCB’s continued commitment to leading research aimed at improving treatment outcomes for people living with neurological conditions.Data include the use of FINTEPLA®▼ (fenfluramine)1 in Dravet ...
The Stanley Brothers created Charlotte's Web, the CBD supplement that’s worked wonders on seizures. Now they are developing ...
UCB has shared promising results from a late-stage study of fenfluramine in patients with an ultra-rare form of epilepsy. The ...
UCB has announced that its phase 3 trial evaluating fenfluramine in CDKL5 deficiency disorder (CDD) achieved its primary and ...
UCB announces positive results from GEMZ phase 3 study of fenfluramine in CDKL5 Deficiency DisorderPhase 3 study met primary and key secondary clinical endpoints, marking the third developmental and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results